Novo Nordisk slams Danish Medicines Council's methodology: Has flaws and shortcomings

Novo Nordisk’s Danish management has sent a strongly worded letter criticizing the Danish Medicines Council’s use of meta-analysis following the release of Denmark’s first treatment guideline for type 2 diabetes.

Kasper Bødker Mejlvang, general manager for Denmark and Iceland at Novo Nordisk | Photo: Novo Nordisk / PR

A few weeks ago, Novo Nordisk expressed its discontent in a letter sent to the Danish Medicines Council over its treatment guidelines for type 2 diabetes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs